caa a22 4500 445332336 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10198-010-0237-3 doi (NATIONALLICENCE)springer-10.1007/s10198-010-0237-3 The costs of breast cancer prior to and following diagnosis [Elektronische Daten] [Steven Broekx, Elly Hond, Rudi Torfs, Anne Remacle, Raf Mertens, Thomas D'Hooghe, Patrick Neven, Marie-Rose Christiaens, Steven Simoens] This retrospective incidence-based cost-of-illness analysis aims to quantify the costs associated with female breast cancer in Flanders for the year prior to diagnosis and for each of the 5years following diagnosis. A bottom-up analysis from the societal perspective included direct health care costs and indirect costs of productivity loss due to morbidity and premature mortality. A case-control study design compared total costs of breast cancer patients with costs of an equivalent standardised population with a view to calculating the additional costs that can be attributed to breast cancer. Total average costs of breast cancer amounted to 107,456 € per patient over 6years. Total costs consisted of productivity loss costs (89% of costs) and health care costs (11% of costs). Health care costs did not vary with age at diagnosis. Health care costs of breast cancer patients converged with those of the general population at 5years following diagnosis. Patients with advanced breast cancer stadia had higher health care costs. Cost estimates provided by this analysis can be used to determine priorities for, and inform, future research on breast cancer. In particular, attention needs to be focussed on decreasing productivity loss from breast cancer. Springer-Verlag, 2010 Breast cancer nationallicence Cost analysis nationallicence Resource utilization nationallicence Health care costs nationallicence Productivity loss nationallicence Flanders nationallicence Broekx Steven Flemish Institute for Technological Research, Boeretang 200, 2400, Mol, Belgium aut Hond Elly Flemish Institute for Technological Research, Boeretang 200, 2400, Mol, Belgium aut Torfs Rudi Flemish Institute for Technological Research, Boeretang 200, 2400, Mol, Belgium aut Remacle Anne Christian Health Insurance Funds, Haachtsesteenweg 579, 1031, Brussel, Belgium aut Mertens Raf Christian Health Insurance Funds, Haachtsesteenweg 579, 1031, Brussel, Belgium aut D'Hooghe Thomas University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium aut Neven Patrick University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium aut Christiaens Marie-Rose University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium aut Simoens Steven Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Onderwijs en Navorsing 2 bus 521, Herestraat 49, 3000, Leuven, Belgium aut The European Journal of Health Economics Springer-Verlag 12/4(2011-08-01), 311-317 1618-7598 12:4<311 2011 12 10198 https://doi.org/10.1007/s10198-010-0237-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0237-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Broekx Steven Flemish Institute for Technological Research, Boeretang 200, 2400, Mol, Belgium aut NATIONALLICENCE 700 1- Hond Elly Flemish Institute for Technological Research, Boeretang 200, 2400, Mol, Belgium aut NATIONALLICENCE 700 1- Torfs Rudi Flemish Institute for Technological Research, Boeretang 200, 2400, Mol, Belgium aut NATIONALLICENCE 700 1- Remacle Anne Christian Health Insurance Funds, Haachtsesteenweg 579, 1031, Brussel, Belgium aut NATIONALLICENCE 700 1- Mertens Raf Christian Health Insurance Funds, Haachtsesteenweg 579, 1031, Brussel, Belgium aut NATIONALLICENCE 700 1- D'Hooghe Thomas University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium aut NATIONALLICENCE 700 1- Neven Patrick University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium aut NATIONALLICENCE 700 1- Christiaens Marie-Rose University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium aut NATIONALLICENCE 700 1- Simoens Steven Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Onderwijs en Navorsing 2 bus 521, Herestraat 49, 3000, Leuven, Belgium aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/4(2011-08-01), 311-317 1618-7598 12:4<311 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer